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 INTRODUCTION 
 Intermittent preventive treatment in pregnancy (IPTp) with 
sulfadoxine pyrimetamine (SP) has been recommended by the 
World Health Organization (WHO) to protect women from 
malaria during pregnancy since early 2000s. 1 Malaria during 
pregnancy is responsible for maternal anemia and low birth 
weight, which are major risk factors for morbidity and mor-
tality during the first 1 year of life. 2– 4 Before 2004, malaria 
prophylaxis with chloroquine (CQ) was the official policy for 
pregnant women in all West African countries, but the quick 
increase of parasite resistance to the drug justified a radical 
change to SP-IPTp. 1 
 In Benin, the new national guidelines recommending the 
use of IPTp with SP instead of CQ were only applied to the 
whole territory in 2006. In 2004, a study was set up in the city 
of Ouidah to assess the efficacy of CQ prophylaxis in preg-
nant women during 1 year before the onset of an IPTp clinical 
trial. 5 This trial was carried out between 2005 and 2008 to com-
pare SP-IPTp with IPTp combined with mefloquine (MQ), 
with the aim to identify an alternative molecule to replace SP 
when it loses its efficacy. 6, 7 In June 2007, a third study was car-
ried out in Tori Bossito, a rural zone in the neighborhood of 
Ouidah, focusing on the occurrence of first malaria infections 
in infants. In this area, the national SP-IPTp had been imple-
mented for over year. 8 
 The objective of this paper is to compare the efficiency 
of malaria prevention during pregnancy in the three studies 
(before the national implementation of IPTp when CQ pro-
phylaxis was still recommended, in a clinical trial testing IPTp 
with SP versus MQ, and in the context of national IPTp) for 
the two indicators: malaria infection of the placenta (MIP) and 
birth weight. In the last part of the paper, the results of the Tori 
Bossito (TB) study are specifically analyzed to understand the 
characteristics of the distribution of IPTp through the national 
health system and the consequences on public health issues. 
 METHODS 
 Ouidah studies.  The designs of the two studies have been 
described elsewhere. 5, 7 Briefly, an observational study followed 
by a clinical trial was set up in Ouidah, a town located 23 km 
west of Cotonou in Benin, an area where malaria transmission 
is high with two seasonal peaks ( Figure 1 ). In 2004, while the 
national guidelines were still for the prescription of a weekly 
CQ prophylaxis, all women attending the two main maternity 
clinics of the area (Kindji and Hôpital de Zone) were stud-
ied at delivery. Placental infections were determined, and 
birth weights were measured. In the following years (2005–
2008), a clinical trial was conducted in the same maternity 
clinics to compare SP and MQ for IPTp. Women > 3 months 
pregnant, with no recent intake of SP or MQ and no history 
of intolerance to these drugs, were included in the clinical 
trial. The drug intakes were strictly supervised by well-trained 
midwives during antenatal visits (ANVs) and scheduled to be 
administrated at the second and third trimester of pregnancy. 
 Tori Bossito study.  The Tori Bossito study was carried 
out in a rural area of Benin located 17 km north of Ouidah 
( Figure 1 ). All women living in nine villages of the area and 
delivering in one of the three main health centers providing 
birth attendance (Tori Avame, Tori Cada, and Tori Gare) were 
enrolled. This study investigated the relationship between MIP 
and the occurrence of malaria infections in infants during their 
first months of life. It was designed to follow 600 newborns 
clinically and parasitologically during 18 months. This paper 
focuses on the mothers who were included between June 2007 
and July 2008. They all had received IPTp with SP through 
the national health system as recommended by the WHO. 1 
Details about the area and the women have been described 
extensively elsewhere. 8 
 In particular, data relative to the use of IPTp or CQ dur-
ing pregnancy were collected from the women after delivery 
and health records: number of doses and date of last intake of 
IPTp, intake of CQ (yes/no), and duration of prophylaxis. 
 All protocols were approved by the ethics committee of 
the Republic of Benin and the Institut de Recherche pour le 
Développement (IRD) ethics committee. 
 Human immunodeficiency virus status of women.  Human 
immunodeficiency virus (HIV) infection is known to be 
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associated with increased risk of malaria and low birth 
weight (LBW), and it may have affected the occurrence 
of MIP and LBW. In the clinical trial, HIV screening was 
routinely undertaken by the national program during the 
trial, but the HIV status of women was only determined 
for 50% of women. 9 HIV-positive women were excluded 
from the analysis. Generally, the prevalence of HIV is low 
(2%) in this area. 10 At the time of the pre-trial, there was 
no determination of HIV status in the clinics of Ouidah. In 
Tori Bossito, the national program for HIV diagnosis during 
pregnancy began its activities in 2007. Only one maternity 
clinic (Tori Gare, where recruitment was the lowest) proposed 
HIV status determination, and only 9% (57/617) of all women 
of the study were tested for HIV infection (one HIV-positive 
woman with a normal birth weight). Considering the overall 
low HIV prevalence, we decided not to take into account 
these data. 
 Biological methods.  In all studies, thick and thin blood 
smears were performed on the peripheral and placental blood 
of the mothers at delivery.  Plasmodium falciparum asexual 
blood forms were counted on Giemsa-stained smears. A blood 
smear was declared negative when no parasite was detected 
after the count of 500 white cells. 8 
 Statistical procedures.  Comparison between studies.  The 
results of the three studies were compared by univariate 
analysis on MIP, LBW, and other covariates, such as gravidity 
status, education of women, number of ANVs, and use of 
impregnated bed nets. Because the efficacy of IPTp with MQ 
and SP were very close at the end of the clinical trial, both 
arms were kept pooled for the present analysis. 9 When non-
parametric methods were required, a Fisher exact test or 
Kruskall–Wallis test was applied. 
 Risk factors for MIP and LBW.  In a second analysis, risk 
factors for MIP and LBW were analyzed by logistic regression 
on the pooled data from the three studies. For the analysis 
of birth weight, only live singleton births were selected. 
The identification of each study (Ouidah cross-sectional, 
Ouidah randomized trial, and Tori Bossito cross-sectional), 
representing both the type of prevention (CQ, IPTp with 
SP or MQ, and national IPTp with SP) and the quality of 
supervision, was defined as a covariate and included in the 
statistical model. 
 For the multivariate analysis, all variables with a  P value 
of below 0.20 in univariate analysis were initially introduced 
into the model removed after a backward step-wise selection 
procedure, leaving only variables with a  P value below 0.05 in 
the final model. All analyses were performed using Stata v. 8.0 
(Stata Corp., College Station, TX). 
 RESULTS 
 In all three studies, women were studied during a complete 
year (2004 for the Ouidah pre-trial study, 2005 for the Ouidah 
clinical trial, and 2007–2008 for the Tori Bossito study) to 
account for seasonal variations in malaria transmission. 
 Study populations.  In Ouidah, recruitment was done in the 
same maternity clinics (Kindji and Hopital de zone) for both 
studies. Data analysis was performed on 1,090 women in the 
pre-trial study and in 609 women in the clinical trial (restricted 
to the first 1 year of the study and women taking SP or MQ). 
In the pre-trial study, 95% of the women had taken CQ, with 
a mean self-reported duration of prophylaxis of 5 months. In 
the clinical trial, with a close follow-up of the women, 95% 
had received two IPTp doses. Analysis on LBW was done after 
excluding twins (47) and stillbirths (62; 55 in the pre-trial study 
and 7 in the trial). 
 In Tori Bossito, 660 women were eligible for the study. 
Among them, 31 refused or did not meet inclusion criteria; 
629 deliveries were observed in the three maternity clinics of 
the area, resulting in 656 newborns (603 singletons, 25 twins, 
and 1 triplet). Ten pregnancies ended with a stillbirth. Data 
were missing for 12 women who had stillbirths or early neo-
natal death and their offspring. Finally, analysis of the moth-
ers was done on 617 women. Excluding twins and triplets, 590 
newborns could be analyzed for LBW. 
 Women and newborns characteristics.  In the two studies 
carried out in Ouidah, 24% of the women were primigravidae, 
and 50% did not receive scholar education. The average age of 
women was 25 years, and 68% were from the Fon ethnic group. 
More information about women’s characteristics for these two 
studies is presented elsewhere. 5, 7 
 Figure 1.  The two study sites of Ouidah (two maternity clinics) 
and Tori Bossito (three maternity clinics), Benin (from Charlotte 
Pierrat, IRD UMR 216, Paris, France ). 
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 In Tori Bossito, 14.8% of the women were primigravidae, 
and 84.8% of the women did not receive scholar education. 
The average age of women was 27.5 years (standard deviation 
[SD] = 5.6); 72.5% were from the Tori ethnic group, 10.6% 
were from the Fon ethnic group, and 16.9% were from other 
groups (Yoruba, Mina, and others). Of the women, 32.6%, 
47.9%, and 19.5% delivered in the maternity clinics of Tori 
Avamè, Tori Cada, and Tori Gare, respectively ( Table 1 ). 
 Comparison of the three studies.  Table 1 presents the 
comparison of the three studies in terms of MIP, LBW, and 
covariates. The comparison between women from the pre-
trial study and the clinical trial in Ouidah, already presented 
in Briand and others, 7 showed no difference on general 
characteristics between the two groups of women. However, 
the proportions of primigravidae, type of education of women, 
number of ANVs, and rates of impregnated bed nets varied 
significantly between Ouidah and TB. The proportion of 
primigravidae was lower in the TB study (14.8% versus 
24.5% and 23.8% in the Ouidah pre-trial and clinical trial, 
respectively), and women were slightly older. Women from 
the rural area of TB were more frequently unschooled than 
those in the already urbanized zone of Ouidah (84.8% versus 
50.1% and 47.4%). Concerning ANVs, the clinical trial 
showed that 73.7% of women had attended more than three 
visits (probably related to the investigators’ good supervision 
of women). These proportions were 62.8% in the pre-trial 
study and only 56.3% in the rural area of Tori Bossito. The 
use of impregnated bed nets was lower in TB (66.3%) than in 
Ouidah (approximately 75% in both studies). 
 Rates of MIP and LBW varied significantly between the 
three studies. The proportion of MIP was 16.7% during the 
Ouidah pre-trial study, 2.9% in the Ouidah clinical trial, and 
11.2% in the TB study. For LBW, proportions were close to 
each other in the Ouidah clinical trial and in TB (8.7% and 
10%, respectively) compared with 15.7% in the pre-trial study. 
The mean birth weight was 2,979 g in TB, 3,059.8 g in the 
Ouidah clinical trial, and 2,876.2 g in the Ouidah pre-trial. 
 Risk factors for MIP and LBW.  When analyzing the pooled 
data from the three studies, placental malaria was found to 
be significantly associated with the women’s gravidity and 
the study, as shown in  Table 2 . Primigravidae had a 2.3-fold 
increased risk to present MIP at delivery compared with 
multigravidae. After adjusting on gravidity, the effect of age 
on MIP disappeared. Women from the Ouidah clinical trial, 
whose IPTp was given in a context of strict supervision, or 
women taking the national IPTp in TB had significantly 
reduced risks to present MIP compared with women from the 
Ouidah pre-trial study who were still taking a CQ prophylaxis 
(adjusted odds ratio [aOR] = 0.15, 95% CI = 0.09–0.24 and 
aOR = 0.67, 95% CI = 0.50–0.91, respectively). 
 Similarly, LBW was found to be associated with the occur-
rence of MIP, gravidity status, use of bed nets, number of 
ANVs, newborn’s gender, and study ( Table 3 ). Women present-
ing MIP had an increased risk to give birth to an LBW baby 
 Table 1 
 Comparison between the three studies in Benin 
Ouidah pre-trial study (2004–2005) Ouidah clinical trial (2005–2008) Tori Bossito (2007–2008)  P * 
Number of women 1,090 609 617
Area Semi-rural Semi-rural Rural
Malaria prophylaxis CQ IPTp (SP or MQ) IPTp SP (±CQ)
Gravidity status
Multigravidity 823 (75.5) 464 (76.2) 522 (85.2)
Primigravidity 267 (24.5) 145 (23.8) 91 (14.8)  P < 10 −3 
Mean age (years) 25.4 (SD = 5.9; range = 13–44) 25.2 (SD = 5.5; range = 15–45) 27.4 (SD = 5.6; range = 16–49)  P < 10 −3 
Age class
≤ 20 255 (23.8) 141 (23.1) 84 (13.8)
21–25 373 (34.8) 230 (37.8) 149 (24.4)  P < 10 −3 
26–30 244 (22.8) 145 (23.8) 217 (35.5)
> 30 200 (18.6) 93 (15.3) 161 (26.3)
Education of women
No education 527 (50.1) 289 (47.4) 519 (84.8)
Partial primary 359 (34.2) 231 (37.9) 64 (10.5)
Complete primary 165 (15.7) 89 (14.6) 19 (3.1)
Secondary or more 0 (0) 0 (0) 10 (1.6)  P < 10 −3 
Number of ANVs
≤ 3 ANVs 400 (37.2) 157 (26.3) 255 (43.7)
> 3 ANVs 676 (62.8) 439 (73.7) 329 (56.3)  P < 10 −3 
Placental malaria † 
Yes 176 (16.7) 17 (2.9) 68 (11.2)
No 876 (83.3) 568 (97.1) 538 (88.8)  P < 10 −3 
Bed net use
No 246 (24.4) 155 (25.4) 204 (33.7)
Yes 764 (75.6) 454 (74.55) 401 (66.3)  P < 10 −3 
Gender
Female 568 (52.1) 285 (46.9) 288 (49.2)  P = 0.11
Male 522 (47.9) 323 (53.1) 298 (50.8)
Average birth weight (g) 2,876.2 (SD = 491.2; 
range = 800–5,000)
3,059.8 (SD = 433.3; 
range = 1,340–4,434)
2,979.0 (SD = 402.2; 
range = 1,430–4,460)
 P < 10 −3 
LBW
No 916 (84.3) 556 (91.3) 529 (90.0)  P < 10 −3 
Yes 171 (15.7) 53 (8.7) 59 (10.0)
 CQ = chloroquine; MQ = mefloquine; IPTp = intermittent preventive treatment; ANVs = antenatal visits; CI = confidence interval; SD = standard deviation. 
 *  Statistically significant ( P < 0.05). 
 †  Defined as the presence of asexual stage parasites in the placental thick blood smear. 
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(aOR = 1.66, 95% CI = 1.15–2.40;  P = 0.01). Primigravidae had 
an over 2-fold increased risk to have a LBW newborn com-
pared with multigravidae (aOR = 2.50, 95% CI = 1.87–3.36; 
 P = 10 −3 ). As for MIP, the effect of age disappeared after adjust-
ing on gravidity. Female babies were more at risk than males to 
suffer from LBW ( P < 10 −2 ). Women sleeping under bed nets 
and women having attended more than three ANVs had signif-
icantly less LBW than women who did not use bed nets or had 
poor attendance to ANVs ( Table 3 ). Finally, taking IPTp in the 
clinical trial (Ouidah) or through the national context of imple-
mentation (TB) had a protective effect on LBW, with an aORs 
= 0.55 (95% CI = 0.38–0.78) and aOR = 0.57 (95% CI = 0.40–
0.81), respectively, compared with the use of CQ during preg-
nancy in the Ouidah pre-trial study ( P value < 10 −2 for both). 
 Malaria prevention in TB.  In this area where the national 
IPTp policy was implemented, 84% (511/608) of the women 
declared having received at least one dose of IPTp during their 
pregnancy. Rates of IPTp coverage according to the maternity 
clinic were 96% in Tori Avamè and 78% in both Tori Cada and 
Tori Gare. Among women who reported IPTp intakes with 
doses notified in health records, 17.3% (85/492) had taken 
one dose, and 82.7% (407/492) had two doses of SP or more; 
8.9% (54/608) of all women were still taking CQ prophylaxis 
alone, and 7.1% (43/608) had not taken any prophylaxis (CQ 
or IPTp). We eliminated this last group from the following 
analysis. We analyzed the relation between malaria prevention 
and MIP or LBW in the following groups: (1) use of IPTp (at 
least one dose) with or without CQ and (2) use of CQ alone. 
 In the study area, a significant effect of the maternity clinic 
where the delivery had occurred was found, with an increased 
risk to present MIP in women delivering in Tori Cada 
and Tori Gare maternity clinics compared with Tori Avamè 
 Table 2 
 Factors associated with MIP 
 CI = confidence interval; OR = odds ratio. 
 *  Statistically significant result ( P < 0.05). 
Factor
Univariate analysis Multivariate analysis
 P * Crude OR (95% CI) Adjusted OR (95% CI)
Study
Pre-trial Ouidah 176/1,052 (16.7) 1.00 1.00
Trial Ouidah 17/568 (2.9) 0.15 (0.09–0.25) 0.15 (0.09–0.24)  P < 10 −3 
Tori Bossito 68/608 (11.2) 0.63 (0.47–0.85) 0.67 (0.50–0.91)  P = 0.01
Age class
≤ 20 87/468 (18.6) 1.00
21–25 91/730 (12.5) 0.62 (0.45–0.86)
26–30 48/588 (8.2) 0.39 (0.27–0.57)
> 30 31/438 (7.1) 0.33 (0.22–0.51)
Gravidity status
Multigravidity 167/1,754 (9.5) 1.00 1.00
Primigravidity 93/489 (19.0) 2.23 (1.69–2.94) 2.29 (1.72–3.05)  P < 10 −3 
Bed net use
No 81/584 (13.9) 1.00
Yes 167/1,573 (10.6) 0.74 (0.55–0.98)
 Table 3 
 Factors associated with LBW 
 Twins and stillbirths were excluded from analysis of LBW. CI = confidence interval; OR = odds ratio. 
 *  Statistically significant result ( P < 0.05). 
Factor
Univariate analysis Multivariate analysis
 P * Deliveries (%) Crude OR (95% CI) Adjusted OR (95% CI)
Study
Pre-trial Ouidah 171/1,087 (15.7) 1.00 1.00
Trial Ouidah 53/609 (8.7) 0.51 (0.37–0.71) 0.55 (0.38–0.78)  P < 10 −2 
Tori Bossito 59/588 (10.1) 0.60 (0.44–0.82) 0.57 (0.40–0.81)  P < 10 −2 
Placental malaria
No 220/1,956 (11.2) 1.00 1.00
Yes 56/257 (21.8) 2.20 (1.58–3.05) 1.66 (1.15–2.40)  P < 10 −2 
Age class
≤ 20 96/477 (20.1) 1.00
21–25 92/745 (12.4) 0.56 (0.41–0.76)
26–30 50/594 (8.4) 0.36 (0.25–0.53)
> 30 38/446 (8.5) 0.37 (0.25–0.55)
Gravidity status
Multigravidity 172/1,782 (9.7) 1.00 1.00
Primigravidity 110/500 (22.0) 2.64 (2.03–3.43) 2.50 (1.87–3.36)  P < 10 −3 
Bed net use
No 101/596 (16.9) 1.00 1.00
Yes 167/1,600 (10.4) 0.57 (0.44–0.75) 0.70 (0.52–0.94)  P < 10 −2 
Number of visits
≤ 3 ANVs 127/799 (15.9) 1.00 1.00
> 3 ANVs 145/1,429 (10.1) 0.60 (0.46–0.77) 0.64 (0.48–0.84)  P < 10 −2 
Gender
Male 116/1,139 (10.2) 1.00 1.00
Female 166/1,142 (14.5) 1.50 (1.16–1.93) 1.60 (1.22–2.12)  P < 10 −2 
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(aOR = 2.42, 95% CI = 1.23–4.78;  P = 0.01 and aOR = 2.48, 
95% CI = 1.12–5.49;  P = 0.02, respectively). There was no influ-
ence of SP-IPTp compared with CQ prophylaxis on the occur-
rence of MIP or LBW (8.9% versus 15.1% and 9.4% versus 
7.8% respectively; not significant). The relationships between 
MIP or LBW and gravidity or use of bed nets in Tori Bossito 
were similar as in the pooled analysis; primigravidity was a risk 
factor for both MIP and LBW, and the use of bed nets was a 
risk factor for LBW only (data not shown). 
 DISCUSSION 
 One year after the national implementation of SP-IPTp in 
Benin, we showed that the overall compliance in the area of 
Tori Bossito was good, with a substantial effect on the reduc-
tion of LBW. This effect was close to the results obtained in 
a randomized trial in the nearby area of Ouidah (10% and 
8.7% LBW, respectively) and much higher than the propor-
tion observed in the pre-trial observation year (15.7%), when 
women were still taking a weekly CQ prophylaxis. However, 
the anti-parasite efficacy was not as good as in the trial (11.2% 
of placenta infection in the delivering women of Tori Bossito 
versus an overall 2.9% in the trial, 2.1% in the MQ group, and 
3.7% in the SP group) in an area where  in vivo resistance to SP 
may reach 50% in children below 5 years. 11 
 Although populations of women were similar between the 
clinical trial and the pre-trial study 7 in Ouidah, differences were 
observed with women from Tori Bossito, although the two sites 
were only 17 km apart. The latter women were less educated 
and had a lower attendance to ANVs, which may be character-
istic of rural areas. Women from Tori Bossito were older, and 
only 15% were primigravidae, possibly because of migrations 
of young women to Cotonou for employment. There are sev-
eral risks of biases in comparing observational studies (Ouidah 
pre-trial study and Tori Bossito study) and a controlled trial and 
more generally, in comparing investigations held in comparable 
sites but at different times. However, even if there may exist dif-
ferences in malaria transmission between sites or differences 
in terms of treatment seeking or patient management between 
maternities, the effect of the study site on MIP or LBW stayed 
unchanged after adjusting on the characteristics of the popula-
tions, and we are confident that the differences observed between 
the sites on these indicators were mainly attributable to the type 
and the mode of administration of anti-malarial prevention. 
 In Tori Bossito, the question of intake of SP-IPTp or CQ dur-
ing pregnancy was asked to the women by the supervisor, and 
doses were copied from the health records. The quality of this 
interview variable is questionable, particularly for the number 
of intakes of SP. Also, some local practices were found to differ 
from the official recommendations; for instance, in the mater-
nity clinic of Tori Cada, two SP doses were given to the pregnant 
women at the first ANV, but they were given with the instruction 
to postpone the intake of the second dose. However, SP-IPTp 
seemed to be more efficacious than CQ prophylaxis in reducing 
MIP (8.9% and 15.1%, respectively), even if the difference was 
not significant. Despite a possible selection of the women tak-
ing only CQ in the study area, these results are consistent with 
the proportion of MIP evidenced by the pre-trial study (16.7%) 
and the very high rate of  in vivo resistance to CQ (85.7%) found 
in Ouidah children in 2005. 11 More surprising is the proportion 
of LBW, slightly higher in the SP-IPTp than in the CQ women, 
although not significantly. Even if the number of women was 
small in the CQ group and the selection of these women was 
probably biased, one cannot rule out the possibility of a direct 
effect (other than anti-parasitic) of CQ on birth weight, as pre-
viously suggested in the pre-trial. 5 A similar study performed in 
2005 assessed the impact of a national IPTp program on preva-
lence of maternal peripheral infection and LBW in Gabon. It 
compared two cross sectional surveys, when CQ was still recom-
mended and 2 years later, after national IPTp implementation. 
The prevalence of maternal peripheral infection dramatically 
dropped from 10.5% to 1.7% (risk ratio = 0.16;  P < 0.001), 
whereas the decrease in LBW was less pronounced (11.7% ver-
sus 10.3%). These results support the main findings of our analy-
sis, showing the strong anti-parasitical efficacy of SP compared 
with CQ and the possible paradoxical effect of CQ on LBW. 12 
 In 2000, African leaders decided at the Abuja conference to 
ensure that 60% of pregnant women could benefit from insec-
ticide treated mosquito nets (ITNs) and have access to IPTp 
by 2005. 13 However, in 2005, only one-half of the countries had 
adopted IPTp. 14 The five first countries (Uganda, Tanzania, 
Malawi, Zambia, and Kenya) that began to use IPTp in the 
1990s because of high rates of resistance to CQ still had, in 
their majority, low rates of coverage after several years of 
implementation. Based on the experiences of these countries, 
Hill and Kazembe 14 in 2006 and Crawley and others 15 in 2007 
aimed to identify facilitating factors and operational challenges 
to improve IPTp distribution, which, in turn, may benefit West 
African countries implementing this policy. Low attendance 
to ANVs and long delays before the first visit (especially in 
women hiding their pregnancy) were among the main reasons 
for low coverage in Uganda. 16 In Gambia and Tanzania as well, 
the intake of two SP doses was quite uncommon. 17, 18 In Tori 
Bossito, women are well-followed during their pregnancy, with 
an average of four ANVs; however, it seems, regarding to ante-
rior studies, that even high rates of attendance to ANVs are 
not sufficient for a good IPTp coverage and uptake, 14 because 
the quality of service delivery and the community perceptions 
and behavior have a great importance as well. 14 
 Among the factors that need to be improved, one of the 
main ones is the poor adherence to the official recommenda-
tions. In the particular context of the clinical trial, doses were 
strictly supervised by well-trained midwives in accordance 
with the directly observed therapy (DOT) scheme, and women 
were looked after by investigators for the second dose. In Tori 
Bossito, compliance with the recommendations that IPTp 
should be given under supervision was lower. Surprisingly, the 
IPTp coverage was not correlated with the staff and equip-
ment of the structures. It was in the best-equipped clinic, Tori 
Cada, that midwives delivered the two SP doses simultane-
ously, thus misusing the DOT scheme. Similar observations 
were made in other African countries. 19, 20 
 Alternately, the low effect of IPTp on reducing MIP in Tori 
Bossito may also be partly related to the increase of parasite 
resistance to SP since 2004, when rates were found to be high 
in Ouidah (50% of parasite resistance to SP). 11 According to 
Brabin and others, 21 there is a need to evaluate IPTp and its 
implementation, coverage, and efficacy regularly. Even if SP 
is still providing substantial benefit to pregnant women in 
areas of parasite resistance to SP (until 25%, according to ter 
Kuile and others 22 ), data about  in vivo resistance to SP by the 
mean of studies on school-aged children are not available any-
more. The level of parasite resistance to SP has to be assessed 
in every area of malaria transmission, in addition to  in vitro 
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studies and studies detecting molecular markers of resistance, 
by the regular observation and analysis of several indicators 
(rates of LBW, MIP, peripheral infection, and anemia). 21, 23 
 In conclusion, even if IPTp implemented in the area of Tori 
Bossito still lacks adherence to the DOT scheme, with varia-
tions from one clinic to the other, the overall compliance in 
pregnant women is among the highest recorded in Africa and 
in 2006, reached the Roll Back Malaria (RBM) objective of 
80% of women taking IPTp by 2010. 24 In terms of efficacy, the 
results of the strategy were quite encouraging on the reduc-
tion of LBW, but some progress has to be made to improve the 
anti-parasite effect on the placenta in a context of moderate 
parasite resistance to SP, probably related to an inadequate 
number and spacing of IPTp doses actually taken. In the near 
future, health workers and midwives should be trained to bet-
ter apply the IPTp strategy and particularly, the DOT scheme. 
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